{"name":"Cybin IRL Limited","slug":"cybin-irl-limited","ticker":"","exchange":"","domain":"cybinirllimited.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CYB003","genericName":"CYB003","slug":"cyb003","indication":"Treatment-resistant depression (Phase 3)","status":"phase_3"},{"name":"CYB004","genericName":"CYB004","slug":"cyb004","indication":"Treatment-resistant depression","status":"phase_2"}]}],"pipeline":[{"name":"CYB003","genericName":"CYB003","slug":"cyb003","phase":"phase_3","mechanism":"CYB003 is a psilocybin-assisted therapy designed to enhance psychological treatment outcomes in psychiatric conditions by facilitating neuroplasticity and emotional processing.","indications":["Treatment-resistant depression (Phase 3)"],"catalyst":""},{"name":"CYB004","genericName":"CYB004","slug":"cyb004","phase":"phase_2","mechanism":"CYB004 is a psychedelic compound that acts as a serotonin 5-HT2A receptor agonist.","indications":["Treatment-resistant depression"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUkI0ZndfVFFucVRwLXBPOUJlRjVyRzNLVzlkU1VaWTg3MzRPY01xTXFaUUVXZkF4SWhJdXNwc1plVUVUOVcyVFhaZHFDdUZ2WTZrY2RYODJlYXVhN2ttTVU3UXhYU0tDeUhrX2xVR0pnTXZVS3NuLWYtVXRUd2xyYUttc0JIaTFsUmhvajdQUS1CS1BWUFRsSF84VXBrV2l4WXJFbEZBRFE?oc=5","date":"2026-03-05","type":"trial","source":"Stock Titan","summary":"Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004 - Stock Titan","headline":"Cybin (CYBN) unit Helus shows promising Phase 2 anxiety results for HLP004","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1EY1BvamhvVHQ5c1prbW04emt1Rkd3bDR2cUhIMlh0NTItWURWTjNiQUtEQ1pTX0RVcm5EcGZtb1RGbVpfdkFGVUNFMWNDVVpzX2kxTDNGMlBoT3BkMmw4?oc=5","date":"2026-02-16","type":"trial","source":"Nature","summary":"A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial - Nature","headline":"A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE92eU1nZG5JNmVibGVnMnE3bFZvRnpFRVJRY1dSTDM5UU1NVEhva24wSnVzd2paeEM1RVg4SjFuTnc1Y19ONkFEbGE5ZHVhbEl0VjdyUEZrU1JOQkRtQmJvN2Mxcw?oc=5","date":"2026-01-02","type":"pipeline","source":"TradingKey","summary":"CYBN|Cybin Inc|Price:8.280| - TradingKey","headline":"CYBN|Cybin Inc|Price:8.280|","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOR0l4UjBFdS1mTWFET0NUaTNWSXlvcjdrd2ljdjJaa0lsNGRkNHJEQk9HRGZHWER2RjF5bE12emwza2I3UUFINnBiT21WaGRzTzVPSEthTkFhSlZGMEYwQ0Rrdk9Qd1h5eU9uZUJVcUdJd050d2pyeEhaWmJOTUZ5THpHUF9OeURzSXpYX0F5SjIxYUlkSDlWajVBYkRmOXg4WkZxd2hDTllfYU9sZktSZFFGRHk2MUZ4TF9nNjVBRDVDdUViTWlMMGo5cnRUY1d1LTNKbFJWWEJnbG9QZW53V3BuSkw3YVN4QlFzUVdDSTE0aXRCUHNEOF9WTFI2elpkWW5WTXMxZDBoWUUtLWhIbnBtSGVMQ3JrelE?oc=5","date":"2025-08-08","type":"regulatory","source":"BioSpace","summary":"Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace","headline":"Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatme","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxOd0p6eTU0bHJFbDFqSV84R1BRcm01TF8yVlplZnE3VVE2dTJKOHR5ZFdOLWlKT2ZnbHlfdlBMNm9lVXVmMnBpejd2ajRxeEhhQk1CRHNPZE5GQ1VaYUJmanNuME5idFhJaW9BbnhmR0haTFRjWXZ3MlpKQ25EVnNHMVAyc0VWT2VubnN1SnpLRXliUGZLNFpfZGU1MEt5akluVTVZOTdpTHZXRjVobnVicVU3TGNIeTFoa0Z2azBYM0txclRDZVhDOFNkNTEtcE9ZREVFVW5xZ1JhV3lTVnZxRXNsQ3huZi15ZUEyS1dHcnIzZWlOX0hIZ0hCMGRLdWl6U01PcmZZcG1FLWhneWVGQzdtSmdlVk1PLUVrRlcxc1BRT2dmRFFHekN6TGlXYlZ3VzBRd3Vn?oc=5","date":"2025-01-22","type":"trial","source":"GlobeNewswire","summary":"5-HT2 Agonist Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"5-HT2 Agonist Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxOZUtzY0N4d3FndW05bER3ektpcnlBSWxjWWpDZ0ZRZmctMkdnOUZQdllGbkJwYnZTTnpIcXoyU1QtenIwaEgtNzAyRTROUW8xTUx4ZkhteXliX0xhLWV5Z2lqdnVsR29kSlJoaTZ3RGRzWG9MRUdIRmU5T0EwaDcycm1UU0QwWm9qaFdPZnFDWE5BaS16RUhla25fUkhyTkQ2RThiaGtpcGNvdXJhTTlweXlkMVotZGV4elZMelN4MVBSSFRHbXpWWGVZbFhPVlFiM1BvTUdDdkRjLUhCMHlSVThJYmVXRlFkdVFVUUpiXzg4NXlJRmRUNGZBR3QxaGFSeGdWMmpYSVQzeklLbnNMS0VsMA?oc=5","date":"2023-10-22","type":"pipeline","source":"businesswire.com","summary":"Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics - businesswire.com","headline":"Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Ther","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQYTZhUGtxRkNwdzhVcUpzSWdvbk9DZ1NpTVV6ajFuczNEdkhVOFRxc21DYXd6QVlUVG1WcFVfZ3lINE1DeVhxNjhzUUl1VkhGZWt1SXI3V0R0UUZuQktERVV5TjZKWjFveXRnTkMwOTViTTFYeC02Yk5reE1aSEgwbU95RnBGbDhuVUctbk5kd0stcDRxRE5MN3R5c2VUMFU3RHFSRzJvamc1WDE1X0duTQ?oc=5","date":"2023-10-17","type":"regulatory","source":"businesswire.com","summary":"Small Pharma Obtains Final Order Approving Arrangement - businesswire.com","headline":"Small Pharma Obtains Final Order Approving Arrangement","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOejhORDBoT3p6NF9OLVpaYk9URDZEaG1rZFVSNGJZX2ZXZHlzbTNkTU9iWUZNVWpRTG9FLVhxXy1wbUxocXdFcENQMzZNTmU2dXlzM3BzbGZyMXNIblpFdHpXMWNqOGVlQ0dYcDBRcjVGbWxIc2V4c1BiRUNMX3pXMWFiWGVxMnpsdlcxMHNzRGFlZ1lxUUFvbFpmdVNpVWhKSVVsSm9hUGlHVXB3dXFMbGJ3S1FEWEU?oc=5","date":"2023-09-20","type":"deal","source":"USA Today","summary":"Cybin to Acquire Small Pharma Inc. - USA Today","headline":"Cybin to Acquire Small Pharma Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQ3JRbXhfUHpRZnd0ZV9JYXE0cGQyNWR1d2x1NEtjbjY2QnJNNG8xTHlFRjZOeWdiZ3pDeVh3VWNjOHVmaWJQTHlsUjRBc2FNa205MWU2Nnp1M1dfc2RzWHhDdlNhY0pzdHJpY0lFNVo2TW1RWGExd0U4UzdOa1BNS2ZET2pJZmN5eXVYSXUwMnFGZUhScEFVQUNLRloxWlhTbUJPdHg2clF0OFZLYXNWcWU3YzhIdFpfS2FrMkVQcjFGbFg1dk1hREZjOE9nYS1kSHlLRA?oc=5","date":"2022-09-27","type":"deal","source":"businesswire.com","summary":"Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds - businesswire.com","headline":"Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}